A. Abbas and A. Lichtman, Basic Immunology: Functions and Disorders of the Immune System, 2010.

S. Boutin, V. Monteilhet, and P. Veron, Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors, Human Gene Therapy, vol.21, issue.6, pp.704-712, 2010.
DOI : 10.1089/hum.2009.182

M. Sudres, S. Ciré, and V. Vasseur, MyD88 Signaling in B Cells Regulates the Production of Th1-dependent Antibodies to AAV, Molecular Therapy, vol.20, issue.8, pp.1571-1581, 2012.
DOI : 10.1038/mt.2012.101

A. Martino, M. Suzuki, and D. Markusic, The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver, Blood, vol.117, issue.24, pp.6459-6468, 2011.
DOI : 10.1182/blood-2010-10-314518

A. Zaiss, M. Cotter, and L. White, Complement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors, Journal of Virology, vol.82, issue.6, pp.2727-2740, 2008.
DOI : 10.1128/JVI.01990-07

A. Zaiss, Q. Liu, and G. Bowen, Differential Activation of Innate Immune Responses by Adenovirus and Adeno-Associated Virus Vectors, Journal of Virology, vol.76, issue.9, pp.4580-4590, 2002.
DOI : 10.1128/JVI.76.9.4580-4590.2002
URL : http://jvi.asm.org/content/76/9/4580.full.pdf

G. Rogers, J. Shirley, and I. Zolotukhin, T cells, Blood, vol.129, issue.24, pp.3184-3195, 2017.
DOI : 10.1182/blood-2016-11-751040

F. Mingozzi, Y. Liu, and E. Dobrzynski, Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer, Journal of Clinical Investigation, vol.111, issue.9, pp.1347-1356, 2003.
DOI : 10.1172/JCI200316887

E. Dobrzynski, F. Mingozzi, and Y. Liu, Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer, Blood, vol.104, issue.4, pp.969-977, 2004.
DOI : 10.1182/blood-2004-03-0847
URL : http://www.bloodjournal.org/content/bloodjournal/104/4/969.full.pdf

L. Franco, B. Sun, and X. Yang, Evasion of Immune Responses to Introduced Human Acid ??-Glucosidase by Liver-Restricted Expression in Glycogen Storage Disease Type II, Molecular Therapy, vol.12, issue.5, pp.876-884, 2005.
DOI : 10.1016/j.ymthe.2005.04.024

R. Ziegler, S. Lonning, and D. Armentano, AAV2 Vector Harboring a Liver-Restricted Promoter Facilitates Sustained Expression of Therapeutic Levels of ??-Galactosidase A and the Induction of Immune Tolerance in Fabry Mice, Molecular Therapy, vol.9, issue.2, pp.231-240, 2004.
DOI : 10.1016/j.ymthe.2003.11.015

A. Martino, S. Nayak, and B. Hoffman, Tolerance Induction to Cytoplasmic ??-Galactosidase by Hepatic AAV Gene Transfer ??? Implications for Antigen Presentation and Immunotoxicity, PLoS ONE, vol.104, issue.8, 2009.
DOI : 10.1371/journal.pone.0006376.g008
URL : https://doi.org/10.1371/journal.pone.0006376

J. Finn, M. Ozelo, and D. Sabatino, Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy, Blood, vol.116, issue.26, pp.5842-5848, 2010.
DOI : 10.1182/blood-2010-06-288001

D. Markusic, B. Hoffman, and G. Perrin, Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies, EMBO Molecular Medicine, vol.105, issue.11, pp.1698-1709, 2013.
DOI : 10.1073/pnas.0802866105
URL : http://embomolmed.embopress.org/content/embomm/5/11/1698.full.pdf

S. Han, G. Ronzitti, and B. Arnson, Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction, Molecular Therapy - Methods & Clinical Development, vol.4, pp.126-136, 2017.
DOI : 10.1016/j.omtm.2016.12.010
URL : https://hal.archives-ouvertes.fr/hal-01432085

D. Avola, D. López-franco, E. Sangro, and B. , Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria, J Hepatol, vol.65, pp.776-783, 2016.

G. Gao, C. Lebherz, and D. Weiner, Erythropoietin gene therapy leads to autoimmune anemia in macaques, Blood, vol.103, issue.9, pp.3300-3302, 2004.
DOI : 10.1182/blood-2003-11-3852
URL : http://www.bloodjournal.org/content/bloodjournal/103/9/3300.full.pdf

R. Herzog, J. Mount, and V. Arruda, Muscledirected gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation, Mol, vol.4, pp.192-200, 2001.

Z. Wang, C. Kuhr, and J. Allen, Sustained AAV-mediated Dystrophin Expression in a Canine Model of Duchenne Muscular Dystrophy with a Brief Course of Immunosuppression, Molecular Therapy, vol.15, issue.6, pp.1160-1166, 2007.
DOI : 10.1038/sj.mt.6300161

J. Mendell, K. Campbell, and L. Rodino-klapac, Dystrophin Immunity in Duchenne's Muscular Dystrophy, New England Journal of Medicine, vol.363, issue.15, pp.1429-1437, 2010.
DOI : 10.1056/NEJMoa1000228

K. Flanigan, K. Campbell, and L. Viollet, Anti-Dystrophin T Cell Responses in Duchenne Muscular Dystrophy: Prevalence and a Glucocorticoid Treatment Effect, Human Gene Therapy, vol.24, issue.9, pp.797-806, 2013.
DOI : 10.1089/hum.2013.092
URL : http://europepmc.org/articles/pmc3768239?pdf=render

A. Toromanoff, O. Adjali, and T. Larcher, Lack of Immunotoxicity After Regional Intravenous (RI) Delivery of rAAV to Nonhuman Primate Skeletal Muscle, Molecular Therapy, vol.18, issue.1, pp.151-160, 2010.
DOI : 10.1038/mt.2009.251
URL : https://doi.org/10.1038/mt.2009.251

P. Doerfler, S. Nayak, and M. Corti, Targeted approaches to induce immune tolerance for Pompe disease therapy, Molecular Therapy - Methods & Clinical Development, vol.3, p.15053, 2016.
DOI : 10.1038/mtm.2015.53
URL : https://doi.org/10.1038/mtm.2015.53

F. Puzzo, P. Colella, and M. Biferi, Whole-body rescue of Pompe disease with AAV liver delivery of engineered secretable GAA transgenes, Sci Transl Med

G. Perrin, I. Zolotukhin, and A. Sherman, Dynamics of antigen presentation to transgene product-specific CD4+ T cells and of Treg induction upon hepatic AAV gene transfer, Molecular Therapy - Methods & Clinical Development, vol.3, p.16083, 2016.
DOI : 10.1038/mtm.2016.83

S. Faust, P. Bell, and B. Cutler, CpG-depleted adeno-associated virus vectors evade immune detection, Journal of Clinical Investigation, vol.123, issue.7, pp.2994-3001, 2013.
DOI : 10.1172/JCI68205
URL : http://www.jci.org/articles/view/68205/files/pdf

F. Mingozzi, X. Anguela, and G. Pavani, Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys, Science Translational Medicine, vol.109, issue.4, pp.194-92, 2013.
DOI : 10.1182/blood-2006-03-010181
URL : http://europepmc.org/articles/pmc4095828?pdf=render

J. Chapin, H. Rottensteiner, and F. Scheiflinger, An analysis of bleeding rates and Factor IX consumption in the Phase I/II BAX 335 gene therapy trial in subjects with hemophilia B, Res Pract Thromb Haemost, vol.1, pp.1-1451, 2017.

P. Simioni, D. Tormene, and G. Tognin, X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua), New England Journal of Medicine, vol.361, issue.17, pp.1671-1675, 2009.
DOI : 10.1056/NEJMoa0904377

L. George, A. Giermasz, and S. Sullivan, SPK-9001: adeno-associated virus mediated gene transfer for haemophilia B achieved durable endogenous prophylaxis at levels of activity sufficient to achieve significant mean reduction in annual bleeding and infusions rates in preliminary data from an on-going Phase 1/2a trial, Res Pract Thromb Haemost, vol.1, pp.1-1451, 2017.

W. Miesbach, M. Tangelder, and K. Meijer, Updated results from a dose escalation study in adults with severe or moderate-severe hemophilia B treated with AMT-060 (AAV5-hFIX) gene therapy: up to 1.5 years follow-up, Res Pract Thromb Haemost, vol.1, pp.1-1451, 2017.

J. Pasi, S. Rangarajan, and L. Walsh, Interim results from a Phase 1/2 AAV5-FVIII gene transfer in patients with severe hemophilia A, Res Pract Thromb Haemost, vol.1, pp.1-1451, 2017.

E. Zinn, S. Pacouret, and V. Khaychuk, In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector, Cell Reports, vol.12, issue.6, pp.1056-1068, 2015.
DOI : 10.1016/j.celrep.2015.07.019

B. György, Z. Fitzpatrick, and M. Crommentuijn, Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in??vivo, Biomaterials, vol.35, issue.26, pp.7598-7609, 2014.
DOI : 10.1016/j.biomaterials.2014.05.032

L. Tse, K. Klinc, and V. Madigan, Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion, Proceedings of the National Academy of Sciences, vol.22, issue.24, pp.4812-4821, 2017.
DOI : 10.1038/gt.2015.69
URL : http://www.pnas.org/content/114/24/E4812.full.pdf

V. Monteilhet, S. Saheb, and S. Boutin, A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8, Molecular Therapy, vol.19, issue.11, pp.2084-2091, 2011.
DOI : 10.1038/mt.2011.108

L. Chicoine, C. Montgomery, and W. Bremer, Plasmapheresis Eliminates the Negative Impact of AAV Antibodies on Microdystrophin Gene Expression Following Vascular Delivery, Molecular Therapy, vol.22, issue.2, pp.338-347, 2014.
DOI : 10.1038/mt.2013.244

J. Mimuro, H. Mizukami, and S. Hishikawa, Minimizing the Inhibitory Effect of Neutralizing Antibody for Efficient Gene Expression in the Liver With Adeno-associated Virus 8 Vectors, Molecular Therapy, vol.21, issue.2, pp.318-323, 2013.
DOI : 10.1038/mt.2012.258

C. Unzu, S. Hervás-stubbs, and A. Sampedro, Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates, Journal of Translational Medicine, vol.10, issue.1, p.122, 2012.
DOI : 10.1111/j.1399-3062.2009.00407.x
URL : http://doi.org/10.1186/1479-5876-10-122